Bronchospasm Secondary to Replacement Estrogen Therapy Lynell C. Collins, M.D., F.C.C.P, Alan Peiris, M.D. CHEST Volume 104, Issue 4, Pages 1300-1302 (October 1993) DOI: 10.1378/chest.104.4.1300 Copyright © 1993 The American College of Chest Physicians Terms and Conditions
FIGURE 1 A, Peak expiratory flow rate (PEFR) at baseline, during estrogen treatment, and after termination of estrogen treatment. Although this is an effort-dependent test, the patient reliably reproduced each measurement on three separate attempts. Each point represents the best of three efforts made near 10 AM daily. B, Forced expiratory volume in 1 s (FEV1) at baseline and during estrogen treatment. Before repeat pulmonary function testing could be performed, the patient suffered myocardial infarction and died from complications. CHEST 1993 104, 1300-1302DOI: (10.1378/chest.104.4.1300) Copyright © 1993 The American College of Chest Physicians Terms and Conditions